Gene · 1439
NIH grants1,415
NIH grants whose papers are about the gene, through NIH's grant-paper links.
101 to 120 of 1,415
Download this page as JSON| Grant | Title | CSF2RB papers | Newest fiscal year |
|---|---|---|---|
| R01AI172089 | Critical role for Solute Carrier Proteins (SLCs) for mast cell function | 1 | 2025 |
| R01AI175149 | Prostaglandin E2-Dependent Control of a Mast Cell IL-33/ST2 Pathway in Asthma | 1 | 2025 |
| R01AR031737 | Regulation of Epidermal Development and Differentiation-Renewal | 1 | 2025 |
| R01AR050452 | Skin Stem Cells and Their Niche Interactions | 1 | 2025 |
| R01CA051497 | Defining the Role of the Cancer Circadian Clock in Tumor Immunity and Tumorigenesis | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 1 | 2025 |
| R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 1 | 2025 |
| R01CA218278 | Degrading therapeutically important kinases using small molecules | 1 | 2025 |
| R01CA245139 | MIRDcell Version 3 | 1 | 2025 |
| R01CA256188 | Probing cytosolic nucleic acid sensing pathways in cancer | 1 | 2025 |
| R01CA259273 | Defining epigenetic mechanisms in NPM1c mutant leukemia | 1 | 2025 |
| R01CA259581 | Elucidating the Functional and Mechanistic Roles of LINE-1 Retrotransposons in Myeloid Leukemia | 1 | 2025 |
| R01CA263079 | Reprogramming myeloid cells to inhibit cancer development | 1 | 2025 |
| R01CA280414 | Multi-cellular interactions defining the human brain metastatic niche | 1 | 2025 |
| R01CA280572 | Dissecting the impact of tumor-intrinsic chromosomal instability on the cancer ecosystem | 1 | 2025 |
| R01DK018381 | Studies on the structure of basement membranes | 1 | 2025 |
| R01DK050107 | Transcriptional Control of Hemoglobin Synthesis and Erythrocyte Development | 1 | 2025 |
| R01DK068634 | Hematopoietic Regulation via GATA Switches | 1 | 2025 |
| R01DK069921 | The Laminin Receptors in Kidney Disease | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1439/grants?page=6